AbbVie and C2N Enter into a Worldwide License Agreement
News Mar 27, 2015
AbbVie has announced that it has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders. This partnership builds upon AbbVie's commitment to pursue transformational disease-modifying therapies in Alzheimer's Disease.
Tau stabilizes proteins that are responsible for the structure and transport in neuronal cells.
Abnormal accumulation of altered tau protein is a leading indicator in a variety of neurodegenerative conditions including Alzheimer's Disease, Progressive Supranuclear Palsy and Corticobasal Degeneration. In these conditions, the development of tau pathology strongly correlates with clinical disease progression.
"The need for new approaches and therapies to address Alzheimer's disease is critical," said Jim Sullivan, Ph.D., vice president, pharmaceutical discovery, AbbVie.
Sullivan continued, "C2N's portfolio of anti-tau antibodies represents one of the most promising approaches to delaying progression of devastating neurodegenerative disease. Combining the world class expertise in Alzheimer's Disease at C2N with AbbVie's proven capabilities in neuroscience will enable the rapid advancement of anti-tau antibodies into patients."
Can a Common Ingredient in Laundry Detergent Help Advance Diabetes Research?News
Two oxygen-producing compounds – including one that boosts performance in some laundry detergents – might one day play a key role in helping scientists successfully build a bioartificial pancreas in the lab to cure type 1 diabetes.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE